Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990-2013 by Doyle, Frank et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Psychology Articles Department of Psychology
1-1-2014
Systematic review and meta-analysis of the impact
of depression on subsequent smoking cessation in
patients with coronary heart disease: 1990-2013
Frank Doyle
Royal College of Surgeons in Ireland, fdoyle4@rcsi.ie
Daniela Rohde
Royal College of Surgeons in Ireland, danielamrohde@rcsi.ie
Aleksandra Rutkowska
Royal College of Surgeons in Ireland
Karen Morgan
Royal College of Surgeons in Ireland, kmorgan@rcsi.ie
Grainne Cousins
Royal College of Surgeons in Ireland, gcousins@rcsi.ie
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Psychology at e-publications@RCSI. It has been accepted for inclusion
in Psychology Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G, McGee H. Systematic review and meta-analysis of the impact of depression
on subsequent smoking cessation in patients with coronary heart disease: 1990-2013. Psychosomatic Medicine. 2014;76(1):44-57.
Authors
Frank Doyle, Daniela Rohde, Aleksandra Rutkowska, Karen Morgan, Grainne Cousins, and Hannah McGee
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/psycholart/62
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/psycholart/62
 -  - 1 
 
 
Systematic review and meta-analysis of the impact of depression on subsequent 
smoking cessation in patients with coronary heart disease: 1990–2013 
Running title: Impact of depression on smoking in CHD 
 
Frank Doyle PhD, Daniela Rohde MSc, Aleksandra Rutkowska MSc, Karen Morgan 
PhD, Grainne Cousins PhD, Hannah McGee PhD 
 
Division of Population Health Sciences (Psychology), Royal College of Surgeons in 
Ireland, Dublin, Ireland 
 
Corresponding author: 
Frank Doyle, PhD 
Department of Psychology, Division of Population Health Sciences, Royal College of 
Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland 
 
Email: fdoyle4@csi.ie, Tel: + 353 1 4022718, Fax: + 353 1 4022764 
 
Word count (including tables/figures and references, excluding appendices): 6964 
Tables: 2, Figures: 2 
 
Author addresses 
 -  - 2 
Division of Population Health Sciences (Psychology), Royal College of Surgeons in 
Ireland, Dublin, Ireland (FD, DR, AR) 
PU-RCSI School of Medicine, Malaysia (KM) 
School of Pharmacy (GC), Royal College of Surgeons in Ireland, Dublin, Ireland 
Faculty of Medicine and Health Sciences, Royal College of Surgeons in Ireland (HM) 
 
Conflicts of interest and sources of funding 
None
 -  - 1 
Abstract  
Objective:  
Smoking cessation is crucial for patients with coronary heart disease (CHD), yet 
depression may impede cessation success. We systematically reviewed the longitudinal 
association between depression and subsequent smoking cessation in individuals with 
CHD in order to quantify this effect. 
Methods:  
Electronic databases (PsychInfo, PubMed, CINAHL) were searched for prospective 
studies of CHD patients which measured depression at baseline (scales, diagnostic 
interview or antidepressant prescription) and reported smoking continuation/cessation at 
follow-up. Inclusive dates were 1st January 1990 to 22nd May 2013. Standardized mean 
differences (SMD) and associated 95% confidence interval (CI) were estimated using 
random effects meta-analysis. Sensitivity analysis explored the impact of limiting meta-
analysis to studies using different depression measures (validated scales, diagnostic 
interviews, antidepressant prescription), different durations of follow-up, or higher quality 
studies. 
Results:  
From 1451 citations retrieved, 28 relevant articles were identified. Meta-analysis of all 
available data from 20 unique datasets found that depressed CHD patients were 
significantly less likely to quit smoking at follow-up (SMD=-.39, 95% CI -.50 to -.29; 
I2=51.2%, p=.005). Estimates remained largely unchanged for each sensitivity analysis, 
except for two studies that used antidepressants, which showed a much larger effect 
(SMD=-.94, -1.38 to -.51; I2=57.7%, p=.124). 
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Conclusions:  
CHD patients with depressive symptoms are significantly less likely to quit smoking than 
their non-depressed counterparts. This may have implications for cardiovascular 
prognosis, and CHD smokers may require aggressive depression treatment to enhance 
their chances of quitting. 
 
Keywords: Depression; coronary heart disease; health behaviors; smoking; smoking 
cessation 
 
Acronyms: 
ACS = acute coronary syndrome,  
BDI (II) = Beck Depression Inventory (II),  
BDI-FS = Beck Depression Inventory Fast Screen, 
CAD = coronary artery disease,  
CCAT = Crowe Critical Appraisal Tool, 
CES-D = Center for Epidemiological Studies Depression Scale,  
CHD = coronary heart disease, 
CI = confidence interval  
HADS = Hospital Anxiety and Depression Scale,  
MI = myocardial infarction,  
MOSSAS = Medical outcomes Study Specific Adherence Scale,  
OR = odds ratio,  
obs = observational study 
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RCT = randomised controlled trial 
PHQ = Patient Health Questionnaire, 
PRIME-MD = Primary Care Evaluation of Mental Disorders, 
SMD = Standardized mean difference 
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Introduction 
 
While smoking cessation should be recommended to all patients (1-3), recent reviews 
have highlighted the importance of smoking in patients with coronary heart disease 
(CHD) (4-6). Smoking cessation is associated with 36-50% reduction in morbidity and 
mortality in CHD patients, with the benefits of quitting smoking outperforming those 
related to other preventive strategies such as blood pressure or cholesterol control (2, 
3). Cessation is especially crucial in this population, as continuing to smoke renders 
such secondary prevention interventions less efficacious (7, 8), therefore smokers are 
not deriving the full benefit from preventive therapies. For example, when comparing 
4424 treated hypertensives, those who smoked had higher levels of suboptimal diastolic 
blood pressure 90mmHg or more (33% vs. 25%), along with higher rates of 
microalbuminuria. Men from the same sample also had higher rates of elevated systolic 
blood pressure of 140mmHg or more (73% vs. 69%), higher left ventricular hypertrophy, 
and microalbuminuria, whereas women smokers had higher cholesterol (8). Similarly, 
Milionis et al. (7) have demonstrated how smokers in primary and secondary prevention 
statin trials have failed to glean full benefits from these lipid lowering drugs, with 
smokers having an extra 23-86% increased risk of a cardiovascular event. While having 
an acute coronary event can motivate smokers to quit, the majority of smokers continue 
to smoke or resume smoking within 6 months after such events (6), therefore identifying 
factors that predict relapse is of significant value for clinicians.  
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The prevalence of depression in patients with coronary heart disease (CHD) is elevated 
in comparison to general population samples (9, 10). Tobacco use has a long-
established relationship with depression. Those who smoke have a higher incidence of 
depressive symptoms, and those with depressive symptoms are less likely to quit 
smoking and are more likely to relapse if they do (4-6). For example, secondary 
analysis of a randomised trial on smoking cessation showed that a greater number of 
nicotine withdrawal symptoms experienced by depressed smokers, as opposed to non-
depressed smokers, mediated the effect of depression on smoking continuation 3-
months later. Indeed, this was estimated to account for 27% of the effect of depression 
on cessation outcomes (11).  It also appears that treating depression in patients with MI 
may not increase cessation rates (12), and it is unclear whether quitting smoking leads 
to an improvement in or worsening of depressive symptoms (13).  
 
Therefore, the effect of depression on subsequent cessation may be profound, 
however, this has not been subject to systematic review or meta-analysis. The 
American Academy of Family Physicians have described the research on the impact of 
depression on lifestyle modifications as “low quantity medium to low quality evidence”, 
and they suggest that further investigation is required (14). Meta-analysis should 
provide a more precise effect estimate than single studies alone. We quantified the 
effects of depression on subsequent smoking in patients with CHD. However, as 
depression is defined in different ways, the potential for misclassification error is high 
which has the potential to distort estimates of the exposures effect (depression) on the 
outcome (smoking), thus resulting in biased estimates of the effect of depression. 
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Similarly, the impact of depressive symptoms may fluctuate over time, or study quality 
could be heterogeneous. We planned a number of sensitivity analyses to address these 
potential biases.  
 
Methods 
This systematic review with meta-analysis was performed according to recommended 
principles (15). 
 
Search strategy 
A systematic literature search of PubMed, CINAHL and PsychInfo was conducted in 
May 2013. Searches used subject headings and keywords. A PubMed example is as 
follows: ((("Depression"[Mesh] OR "Depressive Disorder"[Mesh] OR "Depressive 
Disorder, Major"[Mesh] OR "Adjustment Disorders"[Mesh])) AND "Myocardial 
Ischemia"[Mesh]) AND ("Smoking"[Mesh] OR Smok*)). This search was supplemented 
by handsearching references of retrieved articles. Studies dating from the 1st January 
1990 to May 2013 were included in the analysis. 
 
Study selection and data extraction 
Studies were included if they met the following eligibility criteria: CHD samples, 
published in 1990 or later, prospective, measure of depression at baseline (i.e. 
diagnostic interview, questionnaire, antidepressant prescription, single-item questions), 
measure of smoking at follow-up. We included control groups from (non)randomized 
trials, or combined intervention and control groups from (non)randomized trials (where 
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data for the control groups could not be obtained). We excluded papers which had 
samples exclusively enrolled in cardiac rehabilitation (CR) programs for two main 
reasons. Such programs may have intense behavior modification elements, and should 
have standard measurements of depression and smoking at baseline and outcome. 
Thus, a large body of data exists, but is not necessarily reported in each paper on CR. 
Furthermore, CR participants are not representative of general CHD patients for many 
reasons: not all CHD patients are referred to CR; not all referred patients attend CR; 
those who do attend often drop out; and depression has been shown to predict non-
attendance and drop-out, which may bias estimates (16-18). Two reviewers 
independently completed the first screening of abstracts/titles (DR, AR). Studies that 
were considered eligible for inclusion were read in full and suitability for inclusion was 
independently determined by DR and AR. Disagreements were managed by consensus 
or discussed with a third reviewer (KM or FD). Data were extracted on the basis of study 
setting, % men, length of follow up, depression measures, smoking status (or relevant 
results). Authors were contacted to provide further information when there was 
insufficient data provided in the published paper. 
 
Quality assessment 
The quality of the studies was assessed using the Crowe Critical Appraisal Tool (CCAT) 
(19-21), which was developed based on existing tools, general research methods theory 
and reporting guidelines. It has exhibited a good degree of construct validity (19) and 
reliability (21), and is reported to be simple to implement and suitable for all research 
designs in health. The CCAT consists of eight categories corresponding to various 
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aspects of a study, including introduction, design, sampling, data collection, ethical 
matters, results and discussion. Each category contains a number of items, which are 
marked as present, absent, or not applicable, with only those items that are applicable 
to a specific research design being included in the appraiser’s score. Each category is 
also scored on a scale from 0 (no evidence) to 5 (highest evidence). Scoring is thus not 
based solely on a checklist, but allows for a combined objective (tick boxes) and 
subjective scoring of each category (19). The authors recommend publishing individual 
category scores along with total scores so that weak scores in a category are not 
obscured.  Total scores for each study (ranging from 0-40) are presented as a 
percentage.  
 
Statistical analysis 
Smoking status at follow up was the primary outcome of interest. As some studies used 
multiple measures of depression, these were considered in the following hierarchical 
manner: diagnostic interview, validated scale, current prescription of antidepressants, 
history of depression, single-item (unvalidated) measure. Due to differential 
measurement and reporting of smoking status (e.g. current/former/ex-smoker; smoking 
at least 20 cigarettes in a year) and depression (e.g. scoring above threshold on a 
scale; mean and SD of depression scale for continued smokers and quitters), the 
unadjusted standardized mean difference between depressed and non-depressed 
samples was the primary measure of effect. This was estimated for all included studies 
using the metaeff (22) command in Stata 12.1, and estimated using the random effects 
model (23, 24). The I2 test was used to assess the percentage of variability in the effect 
 -  - 9 
estimates that can be attributed to heterogeneity (variation in effect estimates arising 
from methodological or clinical differences between studies) rather than chance. Pre-
planned sensitivity analysis included examining the impact of differential depression 
assessment (validated scales, diagnostic interviews, antidepressant prescription), 
different durations of follow-up (categorized as <1 year versus ≥1 year), or higher quality 
studies (≥60%) (24). We also assessed whether study design, or the use of adjusted or 
unadjusted estimates affected results. Formal statistical testing for publication bias or 
small study effects was conducted using the Egger’s test which is a sensitive regression 
asymmetry test. Bias is detected by determining whether the intercept deviates 
significantly from zero in a regression of standardized effect estimates against their 
precision. 
 
 
Results 
Study identification 
A flow diagram of the search strategy is presented in Figure 1. The search yielded 1185 
papers of which 1165 were excluded. Twenty-eight explored the association between 
depression and subsequent smoking (11, 12, 25-50). Nine more were omitted (four 
repeat publications (38, 44-46), unavailable data (12, 47, 48, 50), one had too few 
smokers to provide an estimate (49) - see Appendix A). McGee et al. (37) was treated 
as two studies, as two depression scales were used in independent groups to predict 
smoking.  This left 20 datasets from 19 articles for analysis. 
 
 -  - 10 
----------------- 
Fig 1 here 
----------------- 
 
Characteristics of included studies are displayed in Table 1, with studies listed in 
alphabetical order of first author. 
 
----------------- 
Table 1 here 
----------------- 
 
Study Characteristics 
Patients were recruited in hospital settings across 9 countries. Sample sizes at follow-
up ranged from 20–1276. The majority of samples are from patients who presented with 
acute CHD, with the remainder consisting of two studies including both acute and 
chronic CHD patients, two studies with CHD outpatients, and one study being unclear 
(those diagnosed with coronary artery disease after angiography). Length of follow-up 
varied from 1 month to 13 years. Various methods were used to assess depressive 
symptoms, with six studies (30, 31, 33, 37, 41, 43) utilizing more than one measure. 
Two studies used diagnostic interviews (41, 43), 17 used validated scales (11, 26, 27, 
29-37, 39-43), two used antidepressant prescription (25, 30), and one used a single-
item measure of mood (28). Quality appraisals are available in Appendix B. 
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Meta-analysis 
Using the depression measure hierarchy outlined in the Methods, the forest plot using 
the best estimate from individual studies is displayed in Fig 2. 
 
___________ 
Fig 2 here 
___________ 
 
Overall, there is a small effect of depression on cessation across the 20 datasets 
(SMD=-.39, 95% CI -.50 to -.29). There was statistically significant heterogeneity 
evident (I2=51.2%, p=.005). There was no evidence of funnel plot asymmetry indicating 
that the effect of depression on smoking identified in smaller studies was not different to 
larger studies (p=.071 for Egger’s test of asymmetry; see Appendix C for funnel plot).  
 
Sensitivity analyses 
Summary estimates for each of the sensitivity analyses are displayed in Table 2 (and 
Appendix D): 
 
___________ 
Table 2 here 
___________ 
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Estimates were largely unchanged for each of the above conditions. Two studies that 
used anti-depressants demonstrated an effect size that was between 2-3 times larger 
than the other estimates (25, 30). One of these studies contributed to significant 
heterogeneity in the overall estimate and other sensitivity estimates (25), as when it was 
omitted the overall effect remained similar but the heterogeneity was no longer 
significant (SMD=-.34, -.42 to -.26, I2=21.9%, p=.19). The best estimate from the other 
study was the depression scale so this was adopted for the other analyses (30). 
 
Discussion 
Overall, the results of this review suggest that depression is consistently associated with 
significantly reduced likelihood of subsequently quitting smoking in CHD patients. This 
is problematic for CHD patients for two reasons. Firstly, smoking cessation benefits 
CHD patients. Secondly, smoking continuation has a significant negative impact on 
therapies that reduce hypertension and cholesterol (7, 8). Therefore, it is possible that 
depressive symptoms may be contributing to higher cardiovascular risk in smokers by 
reducing the probability of cessation.  
 
Size of effect 
According to guidelines (24), the effect sizes reported here is ‘small’ for all analyses 
except  when analysis is confined to studies defining depression using antidepressant 
prescription. However, even the small estimate is likely to be a clinically significant 
effect, and for example is of similar magnitude to a reduction in post-MI depression 
post-intervention (51). That large effects were demonstrated for antidepressant 
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prescription may seem counter-intuitive, as bupropion SR has been shown to increase 
likelihood of quitting in depressed cardiac patients (11, 52). It is possible that this 
classification may simply reflect those who have more severe depression and are thus 
less likely to quit, but more likely to come to clinicians’ attention for depression and 
receive antidepressants. Furthermore, as antidepressants can be prescribed for other 
problems (pain, other psychiatric conditions, etc.) in those who may not have 
depression, it is possible that such conditions also affect smoking behavior.  Another 
explanation is that the classification as depressed for those using antidepressants or 
sedatives in one of these studies (25) may have significantly inflated the depression 
category, and possibly lead to an overly-large effect size for that study. However, 
caution should be used when interpreting these sensitivity analyses, as there were very 
studies in some categories.  
 
Study quality 
Any conclusions drawn from such meta-analyses must be cognizant of the quality of the 
literature reviewed (24).  While critical appraisal of primary studies is an essential 
feature of systematic reviews, the lack of a ‘gold standard’ appraisal method has been 
acknowledged (53, 54) with many tools lacking information on development, evaluation 
of validity or testing reliability (19). Assuming the CCAT ratings were appropriate, this 
had little effect on our results in sensitivity analyses, and indicates the findings are 
consistent across studies.   
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However, other indicators of quality could be considered. Studies largely relied on self-
report data, which could be considered a weakness, despite the fact that such data has 
excellent sensitivity and specificity for smoking behavior (55). The severity of smoking 
addiction, or number of cigarettes smoked were also typically omitted. Possibly more 
problematic was that studies differed somewhat in their classifications of smokers, or 
did not report the precise criteria used to categorize smokers and non-smokers. 
Furthermore, studies largely did not adjust for other potentially confounding factors 
when reporting the associations of interest, which means that the present results may 
be over-estimates. Similarly, the measurement of depression was heterogeneous. 
Differential measurement of depression can lead to starkly contrasting results when 
predicting prognosis (56, 57). Reassuringly, sensitivity analyses demonstrated similar 
effect estimates for all measures, with the exception of anti-depressants. It is crucial that 
future research adopts recommended definitions of smokers (58), and wherever 
possible incorporates biochemical measures of smoking, and measures of addiction 
severity.  
 
Treatments and hospitalization 
As depression is typically episodic, and chronic, it is possible that the impact of 
depression on subsequent smoking fluctuates, with the highest influence during more 
severe depressive episodes (5). However, sensitivity analysis did not show any major 
effect of follow-up duration on the present results. Given that nicotine is so addictive 
(and smoking is typically an everyday activity) any hypothesized fluctuating effects may 
actually be more important for non-addictive behaviors, such as physical activity. 
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Furthermore, it is possible that depression may have a stronger effect on smoking 
initiation than cessation (59). 
 
While cessation counseling with more than 1-month follow-up has been shown to be 
effective for cardiac patients (1), and can even reduce post-discharge mortality when 
combined with pharmacotherapy (60), no randomized trials have assessed smoking 
interventions in depressed cardiac patients specifically. Available data is limited to post-
hoc analyses, albeit pre-planned (6, 12). Similarly, trials have not examined the safety 
of nicotine replacement therapies (NRT) in acute cardiac patients, and as nicotine has 
direct effects on the cardiovascular system, RCTs for acute patients are needed to 
establish safety (6). These deficiencies in the literature somewhat limit the 
recommendations that can be made regarding specifically targeting depressed CHD 
patients who smoke. 
 
In contrast, nicotine replacement therapy (NRT) has been approved for stable CHD 
patients, and is recommended for selected MI patients as they are being discharged. 
NRT acts on withdrawal symptoms, so may be especially important for depressed CHD 
patients who tend to report higher rates of such symptoms (11). Bupropion SR has been 
shown to be well-tolerated in patients with acute CVD, and to increase subsequent quit 
rates in those with elevated depressive symptoms compared to those without (19% v 
3%), although this was non-significant (p=.07) probably due to limited sample size (11). 
Although varenicline has demonstrated effectiveness in increasing cessation rates in 
stable cardiac patients, caution is needed when prescribing this therapy in those with 
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depression and CHD, due to reported increases in depressed mood and even 
suicidality, and intensive monitoring would be required (6).  
 
Unfortunately, despite hospitalization being a teachable moment for smoking cessation, 
healthcare professionals advise patients to quit less often than they should (1, 61, 62). 
While the results of the present review suggest that depressed CHD patients may 
require more intensive intervention, the use of systematic programs on cessation seem 
to be effective, even when controlling for depression (29, 62). Hospitals should 
implement such systematic programs, and consider screening for depression in 
smokers to target those in need of more intensive intervention (6).  
 
Future research 
The present findings suggest that further, more sophisticated research is required on 
the interactions between depression and smoking. Adding multiple follow-up phases 
with measures of depression and smoking at each phase would provide more detail on 
the effects of depression over time (4). While many studies adjust for smoking status at 
baseline (10), they typically do not account for the number of cigarettes smoked, or 
whether people quit post event, and therefore the full effects of smoking may not be 
assessed properly. Such research may also inform the literature on potential behavioral 
mechanisms linking depression with poorer prognosis in those with coronary heart 
disease (63, 64), as  our results suggest that smoking may be a mediating factor in the 
depression-prognosis link (65). As results were largely unadjusted, it is possible that 
other factors account for the depression-smoking association seen here. Depressed 
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CHD patients have higher cravings, lower confidence in quitting, greater withdrawal 
symptoms, lower sense of coherence, lower social support than non-depressed 
smokers (11, 12, 26, 38, 39), and future research should determine the potential 
interacting effects of these variables. Furthermore, novel therapies such as behavioural 
activation may need to be investigated, as the efficacy for talk therapies appears to be 
mixed for depressed patients (4, 12), and our results highlight the need for establishing 
the best treatments for cessation in depression CHD patients.. Finally, although we 
studied the association between depression and cessation in CHD patients, future 
research should establish whether the effects seen here are similar for other 
populations. 
 
Strengths and Limitations 
The results should be interpreted in the context of the limitations relating to the original 
studies. Although the methodological quality of the included studies was reasonable, 
eight were rated below the threshold of 60%. However, accounting for quality of the 
included studies in a sensitivity analysis did not change the pooled effect. In addition, 
our meta-analysis was restricted to the pooling of unadjusted estimates, thereby failing 
to account for potential confounders. However, the adjusted estimates did not differ 
greatly. Furthermore, although we were able to consider the effect of misclassification 
bias due to different depression measures, we were unable to account for the potential 
influence of different measures of smoking. However, despite the wide variation in 
smoking measures, the results across the individual studies are quite consistent as 
displayed in the forest plot, and when the antidepressant studies are removed, the 
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heterogeneity is no longer significant, thus suggesting the effect is quite robust. There is 
the possibility that some chance findings are being submitted, or that studies, including 
those which measure multiple behaviors, are only reporting those with significant 
associations, and this was supported by some evidence of publication bias. Data were 
pooled from six different countries, enhancing the generalizability of the findings. 
Omission of CR programs also weakens the findings.  
 
Conclusion 
Depression reduces the likelihood of quitting smoking in cardiac patients, and this 
effect remains after adjustment for other factors. Clinicians should consider screening 
for depression in smoking patients with CHD, and provide intensive cessation help. It is 
vital to establish the cessation methods that are most efficacious for depressed CHD 
smokers. 
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Table 1: Prospective studies reporting an association between baseline depression and subsequent smoking 
Author, Country 
 
 
 
 
Study 
design 
Sample, 
% Men  
Sample 
size: 
baseline, 
follow-up 
Longest 
(mean/ 
median) 
follow-up 
duration 
Depression 
measures 
(measured 
at follow-up 
Yes/No) 
Smoking 
Outcome 
measure 
Results Adjusted or 
unadjusted 
Quality 
score 
Comments 
Attebring et al. 
(25), 
Sweden 
Obs ACS, 72% 434, 348 3 months 
Sedatives or 
antidepressa
nts at time of 
admission 
 
(No) 
Self-report. 
Current smokers 
classified as at 
least one 
cigarette/pipe/ 
cigar per day at 
time of admission 
or within month 
prior to admission 
Ex-smokers had 
stopped at least 
one month prior to 
admission 
Smokers taking 
antidepressants or 
sedatives less 
likely to quit 
(OR=8.4, 95% CI 
2.36-30) 
Adjusted for 
history of 
cerebrovascular 
disease, history 
of cardiac event, 
cigarette 
consumption, 
history of 
smoking-related 
pulmonary 
disease, 
participation in 
Cardiac 
rehabilitation 
62.5% 
The classification of depression 
using both sedatives and 
antidepressants may have 
significantly broadened the 
depression category, and 
contributed to a higher effect size. 
Associations for other outcomes 
unavailable. Unadjusted estimates 
used in meta-analysis. Effect size far 
exceeds other research findings, even 
in adjusted analysis. This study is a 
significant source of heterogeneity in 
the meta-analysis. 
Berndt et al., (a) 
(26), The 
Netherlands 
Obs 
Chronic 
or acute 
CHD, 
65% 
133, 108 1 month 
HADS 
 
(No) 
Self-report plus 
nurse reports of 
patients’ smoking 
Association for 
depressed v non-
depressed or 
quitters v non-
quitters not 
reported. High risk 
cluster 1 identified 
from cognitive 
variables (pros 
and cons of non-
smoking, self-
efficacy etc.), 
which had highest 
depression score 
(mean (SD) 5.77 
(3.99) compared 
to 4.19 (2.97) for 
cluster 1 and 4.21 
(3.59) for cluster 
2). Continued 
abstinence at 1 
month was lower 
among cluster 3 
patients (36.1% 
compared to 
68.3% for cluster 1 
and 65.2% for 
cluster 2). 
Unadjusted 57.5% 
Did not measure disease diagnosis 
severity. Cluster 3 included cardiac 
patients with a high risk to resume 
smoking after  discharge. Patients in 
this cluster were characterised by a 
history of cardiac disease, high 
addiction levels, high scores for 
depression, and low intentions toward 
non-smoking. Data for meta-analysis 
obtained via email, predicting 
continued abstinence 
Berndt et al. (b) 
(27), The 
Netherlands 
Obs  
Chronic 
or acute 
cardiac 
patients 
168, 168 6 months 
HADS 
 
(No) 
Self-report 
Significant 
negative 
correlation 
between HADS 
Unadjusted 
correlation. Later 
adjusted for 
nicotine 
70.0% 
Unadjusted results provided on email. 
This is an independent sample from 
the above Berndt study. Most 
conservative adjusted results 
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(majority 
ACS), 
78% 
depression score 
and 7-day 
smoking 
abstinence at 6 
months (r=-.21, 
p<.01) 
dependence, 
craving, study 
hospital, total 
HADS score, 
depression and 
anxiety 
reported that depression accounted 
for 0.2% of variance in abstinence. 
Brummett et al. 
(28), United 
States 
Obs CAD, 72% 525, 505 
Up to 6 
years, 
mean 25.5 
months 
“How 
depressed 
or cheerful 
have you 
been during 
the past 
month?” 
(Likert 0-10) 
 
(No) 
Self-report 
 
Classified as 
smokers if 
reported at least 
one cigarette/day 
for the past 6 
weeks 
40% of full sample 
quit without 
relapse. Those 
depressed 
(scoring 1 
standard deviation 
above mean) more 
likely to continue 
smoking (OR=1.6, 
95% CI 1.12-2.27) 
Adjusted for 
socio-
demographic 
characteristics, 
disease severity 
variables, and 
psychological 
variables 
(hostility, 
concern about 
health, tension, 
depression, lack 
of energy) 
45.0% 
Results represent an average OR from 
repeated measures of different follow-
up times. Unclear how many 
completed depression measure. 
Assumed to be total sample (n=525) 
for estimation of effect size. Authors 
unable to provide original data. 
Dawood et al. 
(29), United 
States 
Obs MI, 67% 834, 639 6 months 
PHQ-9 (>9 
as 
depressed) 
 
(Unclear: not 
included in 
analysis) 
Self-report 
 
Classified as 
smokers if one 
puff in past 30 
days 
Those depressed 
during 
hospitalisation 
were less likely to 
quit than non-
depressed (18% v 
31%; OR adjusted, 
0.57, 95% CI, 
0.36-0.90) 
Adjusted for 
socio-
demographic 
variables, 
medical history 
variables (e.g. 
substance use, 
diabetes, lung 
disease etc.), 
procedures and 
clinical status on 
admission, 
psychosocial 
variables 
(depression and 
social support), 
referral to CR, 
smoking 
cessation 
counselling, 
availability of 
smoking 
cessation 
programme at 
admitting 
hospital, 
enrolment site 
67.5% 
Importantly, association survives 
adjustment for several potential 
confounders. Even though adjusted for 
systematic cessation programmes, 
depression still predictor of 
continuation. Referral to cardiac 
rehabilitation and having a systematic 
cessation programme on site 
predicted cessation when adjusting for 
depression. 
Gravely-Witte et 
al. (30), Canada Obs 
CAD 
outpatie
nts, 
71% 
1498, 1276 9 months 
Anti-
depressant 
prescription, 
BDI-II  
 
(Yes) 
Self-report. 
Current smokers – 
smoking at 
baseline survey 
Former smokers 
had quit prior to 
first assessment 
BDI-II at baseline 
was associated 
with smoking 
status (p<0.01), 
but not change in 
smoking status at 
9-months. 
Smokers on 
antidepressants 
(n=127) less likely 
Adjusted for 
demographic 
and clinical 
differences 
including age, 
sex, co morbid 
conditions, 
overweight/obesi
ty, index MI, 
work status, 
67.5% BDI-II results obtained via email.  
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to quit at follow-up 
than those not on 
antidepressants (3 
v 18%, p=0.03) 
marital status, 
education and 
dyslipidemia 
Holtrop et al. (31), 
United States RCT 
ACS, 
61% 166, 136 
3 and 8 
months 
Self-report 
history of 
depression, 
CES-D 
 
(Unclear – 
not reported 
or included 
in analysis) 
Self-report.  
Classified as 
smokers if 
smoking at 
hospitalisation 
All others 
classified as non-
smokers 
History of 
depression 
associated with 
increased risk of 
relapse when 
compared to 
successful quitters 
(OR=6.38, 95% CI 
2.3–17.3), or 
those who 
continued to 
smoke (OR=2.7, 
95% CI 1.02–7.5), 
but not likelihood 
of quitting 
(OR=0.42, 0.16–
1.4) 
Adjusted for 
socio-
demographic 
characteristics, 
co morbidity, 
intensity of 
smoking, 
presence of 
other smokers in 
household, 
intervention 
group (receiving 
health behaviour 
intervention 
programme, or 
control) 
62.5% 
Analyses data from total recruited 
sample before subsample randomised 
to controlled trial. Trial arm not a 
significant predictor of smoking status. 
Current depression not a predictor of 
cessation, but data not reported and 
authors did not respond to email. 
Unadjusted results used to estimate 
effect size. In adjusted results most 
conservative finding used 
(likelihood of quitting).  
Huijbrechts et al. 
(32), The 
Netherlands  
Obs First MI, 71% 164, 164 5 months 
HADS 
 
(Yes) 
Self-report 
 
Persistent 
smokers had 
higher baseline 
depressive 
symptoms than 
ex-smokers or 
non-smokers 
(p<0.05) Results 
estimated from 
figure 
Unadjusted  45.0% 
Results difficult to interpret, but appear 
to be consistent across three  mood 
scales. Used HADS data for effect 
estimation as it is the only established 
depression scale. 
Jones & West 
(33), United 
Kingdom 
RCT 
MI, % 
men not 
reported 
1128, 568 6 months DSSI/sAD Self-report 
47% of depressed 
v 41% of non-
depressed 
smoking at follow-
up 
Unadjusted 65.0% 
Results obtained on email. High 
dropout rate at follow-up. Sample size 
refers to smokers only. 
Kronish et al. (34), 
United States Obs 
ACS, 
59% 560, 492 3 months 
BDI (<5 
compared to 
>9, scores 
of 5-9 
omitted) 
 
(Yes) 
Self-report 
Classified as 
smokers if smoked 
in the last 7 days 
Persistent 
depression was 
positively 
associated with 
smoking 
continuation.  
Adjusted for 
socio-
demographic 
variables, co 
morbidity  
62.5% 
Persistent depression better predictor 
of outcomes than remitted depression 
in analyses. Results may be 
overestimate since those with 
intermediate levels of depressive 
symptoms omitted.  Results to 
estimate effect size obtained via email. 
Ladwig et al. (35), 
Germany Obs 
MI, 
100% 552, 377 6 months 
Unclear, but 
instruments 
stated to be 
previously 
validated. 
 
(No) 
Self-report 
Relative risk for 
maintenance of 
smoking habits in 
depressed 
compared to non-
depressed was 
2.63 (95% CI 1.23 
to 5.60).  
Adjusted for 
age, social 
status 
(blue/white 
collar), recurrent 
infarction before 
baseline, in-
hospital 
rehabilitation, 
non-fatal cardiac 
events after 
index infarction, 
helplessness, 
50.0% 
Relative risk was used as an odds-
ratio estimate as base rates 
unavailable and author did not 
respond to email. This may 
overestimate effect. 
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post-infarction 
angina, 
medication 
adherence, peak 
values of cardiac 
enzymes 
Mayou et al. (36), 
United Kingdom Obs MI, 73% 344, 224 1 year 
HADS 
(HADS-
D>10, or 
summed 
HADS-A and 
HADS-
D>19) 
 
(Yes) 
Self-report 
Depression 
predicted 
continued smoking 
(41% of distressed 
smokers v 10% of 
10% of non-
distressed at 3-
months), at 1 year, 
the figures were 
47% of distressed 
and 29% of 
nondistressed 
subjects 
Unadjusted 65.0% 
Only ‘distressed’ values, rather than 
depression, were reported (and used 
in the meta-analysis), as the authors 
state that the patterns were similar for 
both HADS anxiety and depression 
scales. No response to email to obtain 
depression-specific data. 
McGee et al. (37), 
Ireland Obs 
ACS, 
76% 598, 447 1 year 
HADS-D (>7 
as 
depressed), 
BDI-FS (>3 
as 
depressed) 
 
(Yes) 
Self-report 
Those depressed 
at baseline 
significantly more 
likely to continue 
to smoke after 
hospitalisation 
(combined 
samples) (OR = 
2.3, 95% CI 1.3–
4.0).  
HADS-D did not 
predict 
continuation of 
smoking at one 
year (OR = 1.6, 
95% CI 0.6-4.3), 
but BDI-FS did 
(OR=2.6, 95% CI 
1.4-5.2) 
Adjusted for site 
of recruitment 82.5% 
This study contained two independent 
samples so separate estimates used 
for HADS and BDI-FS groups.  
Myers et al. (38, 
39), Israel Obs 
Incident 
MI, 86% 632, ? 
13 years  
(mean 
12.33 
±2.75) 
BDI >10 or 
BDI 1-SD 
increase 
 
(No) 
Self-report 
Classified as 
current, former, or 
never smoker 
Depressed less 
likely to stop 
smoking (OR 0.75, 
CI 0.60-0.94, 
p=0.01) 
 
Adjusted for age 
and sex and 
other various 
factors 
depending on 
model reported 
60.0% 
Raw data received on email to 
calculate unadjusted effect size. 
Depression not significant in several 
models, and only becomes significant 
in adjusted model. Sense of 
coherence a consistent predictor of 
cessation. Adjusted results 
represent 1-SD increase in 
depression. 
Pederson et al. 
(40), The 
Netherlands 
Obs 
CAD 
outpatie
nts,  
61% 
28, 20 3 months 
HADS 
 
(No) 
Self-report 
Patients who 
successfully quit 
scored lower on 
depression [mean 
(SD): 5 (3)] than 
those who 
continued smoking 
[mean (SD): 8 (5), 
p=.10] 
Unadjusted 52.5% Pilot programme with small sample. No report of larger dataset found. 
Perez et al. (41), 
Brazil Obs 
ACS, % 
men not 
reported 
628, 403 6 months 
PRIME-MD, 
BDI 
 
(Yes)  
Self-report 
Multivariate 
analysis: relapse 
predicted by major 
depression (46.3% 
v 28.9%: OR= 
2.55, 95% CI 
1.52–4.23). 
Elevated BDI 
scores also 
predicted relapse 
(Mean (SD) BDI: 
15.33 (8.31) v 
12.84 (7.96), 
(p=0.003) 
Adjusted for 
Socio-
demograhic 
characteristics, 
living status, 
stage of change, 
cardiac history, 
cardiac 
diagnosis, 
medication use 
(anxiolytic, anti-
depressant), 
dur tion of 
hospitalisation, 
age of smoking 
onset, number of 
quit attempts 
50.0% 
Association also survived multivariate 
adjustment. Anxiolytic use also 
predicted relapse. Non-adjusted data 
used for estimating effect siz s. 
Adjusted estimat s  
Taylor et al. (42), 
United States Obs MI, 70% 245, 245 3 months 
CES-D 
 
(Yes) 
Self-report 
Depres ion 
associat d with 
smoking 
(t=ms5.87, 
df=241, p<0.001).  
Unadjusted 40.0% 
Unclear if this is cross-sectional or 
prospective  association. Treated as 
prospective as this was stated aim of 
paper. Limited data available.  
Standard error imputed for median 
value as base rates unavailable and 
no response from email request. 
Thorndike et al. 
(11), United 
States 
RCT 
Acute 
CVD, 
71% 
245, 244 12 months 
BDI >15 
 
(No) 
Self-report, 
expired carbon 
monoxide, saliva 
cotinine 
concentration 
Depressed 
smokers more 
likely to resume
smoking by 4 
weeks after 
discharge 
(P=.007; incidence 
rate ratio, 2.40; 
95% CI 1.48-3.78) 
than were 
smokers with 
lower BDI scores 
Adjusted for sex, 
race/ethnicity, 
number o  
cigarettes 
smoked per day,  
Fagerström Test 
for Nicotine 
Dependence 
score 
75.0% 
Only study to use objective measure 
of smoking cessation. Pre-planned 
post-hoc analysis of randomised trial. 
Trend for those depressed smokers 
treated with bupropion SR to be more 
likely to quit (p=.07), but small sample 
size. 
Ziegelstein et al. 
(43)  also (44-46), 
United States 
Obs MI, 57% 276, 204 4 onths 
SCID DSM-
III-R, BDI 
(>9) 
 
(No) 
 
MOSSAS scale
Depression did not 
predict smoking at 
follow-up for either 
MDD/dysthymia 
(Mean (SD) 
MOSSAS score 
2.5 (1.8)] v  3.3 
(2.0)] ) or BDI 
groups ( Mean 
(SD) MOSSAS 
score 2.9 (1.7)] v 
3.4 (1.9)]) 
Unadjusted 70.0% 
Multiple papers from dataset. 
Depression was predictive of other 
outcome behaviours, such as non-
adherence to diet, exercise reducing 
stress or increasing social support. 
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Table 2: Sensitivity analyses 
Sensitivity analysis SMD 95% CI I2 p-value 
Diagnostic interviews -.37 -.57 to -.17 0% .93 
Validated depression 
scales 
-.33 -.42 to -.24 20.8% .21 
Antidepressants -.94 -1.38 to -.51 57.7% .12 
<1 year follow-up -.43 -.58 to -.28 61.6% .001 
≥1 year follow-up -.35 -.5 to -.2 1.8% .40 
CCAT≥60% -.37 -.52 to -.22 61.4% .002 
CCAT<60% -.41 -.54 to -.28 11.4% .34 
Observational studies -.40 -.51 to -.28 43.3% .030 
Randomised Trials -.39 -.74 to -.03 78.7% .009 
Adjusted estimates -.35 -.47 to -.22 50.9% .021 
Unadjusted estimates -.37 -.57 to -.17 44.7% .081 
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Figure 1: Flowchart of selected articles 
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(n=8) 
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Cross-sectional 
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Fig 2.  Forest plot of the impact of depression on subsequent smoking 
cessation 
 
 
